SEC Form 4 · accession 0001834681-26-000001
Niagen Bioscience, Inc. · NAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ozan Pamir
Officer — Chief Financial Officer
Period of report
Jun 30, 2026
Accepted (ET)
Jul 8, 2026 · 5:17 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001386570
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 30, 2026 | A | 4,255 | $2.71 | A | 11,627 | D | |
| Common Stock | holding | — | — | — | 2,220 | I | The reported securities are held by the reporting person's spouse. |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares acquired pursuant to the Issuer's Employee Stock Purchase Plan. The acquisition is exempt under Rule 16b-3(c) and 16b-3(d).